Amber Therapeutics is developing an adaptive, implantable neuromodulation system to treat women’s mixed urinary incontinence. The company’s device targets neural pathways involved in bladder control to modulate dysfunctional signaling that contributes to both stress and urge incontinence. Its platform combines implantable hardware with sensing and stimulation capabilities designed for long-term therapeutic use. The system is intended for deployment within regulated clinical settings.

The technology uses an adaptive neuromodulation approach that adjusts stimulation parameters in response to physiological signals associated with bladder activity. By integrating sensing and stimulation within a closed-loop system, the device aims to tailor therapy to individual patient needs and changing conditions. This adaptive architecture is designed to improve therapeutic consistency while minimizing unnecessary stimulation. The implant is engineered for chronic use, emphasizing reliability and patient comfort.

Amber Therapeutics positions its solution within the clinical treatment landscape for urinary incontinence, focusing specifically on unmet needs in women’s health. The device is intended to be prescribed and managed by clinicians as part of standard care pathways. Its focus on adaptive neuromodulation reflects growing interest in personalized, closed-loop therapies for conditions involving dynamic neural and physiological processes.